Table 1 Characteristics of the study population.
From: Genetics of symptom remission in outpatients with COVID-19
Characteristic | Placebo N = 926 | Colchicine N = 929 | All N = 1855 |
|---|---|---|---|
Age (years), mean SD | 54.4 ± 9.1 | 53.9 ± 9.0 | 54.1 ± 9.1 |
Female sex, n (%) | 499 (53.9%) | 544 (58.6%) | 1043 (56.2%) |
Canada, n (%) | 926 (100.0%) | 927 (99.8%) | 1853 (99.9%) |
Self-reported as white, n (%) | 918 (99.1%) | 924 (99.5%) | 1842 (99.3%) |
BMI (kg/m2), mean SD | 30.3 ± 6.4 | 30.1 ± 6.5 | 30.2 ± 6.5 |
Non-smoker, n (%) | 502 (54.2%) | 475 (51.1%) | 977 (52.7%) |
Previous smoker, n (%) | 357 (38.6%) | 377 (40.6%) | 734 (39.6%) |
Current smoker, n (%) | 67 (7.2%) | 77 (8.3%) | 144 (7.8%) |
History of diabetes, n (%) | 162 (17.5%) | 140 (15.1%) | 302 (16.3%) |
History of hypertension, n (%) | 307 (33.2%) | 289 (31.1%) | 596 (32.1%) |
History of respiratory disease, n (%) | 285 (30.8%) | 260 (28.0%) | 545 (29.4%) |
Asthma, n (%) | 199 (21.5%) | 188 (20.2%) | 387 (20.9%) |
Chronic obstructive pulmonary disease, n (%) | 24 (2.6%) | 30 (3.2%) | 54 (2.9%) |
Pneumonia, n (%) | 25 (2.7%) | 18 (1.9%) | 43 (2.3%) |
Prior MI, PCI or CABG, n (%) | 54 (5.8%) | 45 (4.8%) | 99 (5.3%) |
Prior stroke/TIA, n (%) | 7 (0.8%) | 8 (0.9%) | 15 (0.8%) |
Prior heart failure, n (%) | 9 (1.0%) | 7 (0.8%) | 16 (0.9%) |
Characteristics of study outcomes | |||
Hospitalisation for COVID-19 within 30 days, n (%) | 34 (3.7%) | 24 (2.6%) | 58 (3.1%) |
Days to hospitalisation, mean SD | 6.8 ± 5.4 | 6.3 ± 3.8 | 6.6 ± 4.8 |
Need for mechanical ventilation, n (%) | 1 (0.1%) | 1 (0.1%) | 2 (0.1%) |
COVID-19 symptom remission in 30 days, no | 224 (26.3%) | 245 (28.1%) | 469 (27.2%) |
COVID-19 symptom remission in 30 days, yes | 627 (73.7%) | 627 (71.9%) | 1254 (72.8%) |
Days from randomisation to end of symptoms, mean SD | 11.7 ± 7.2 | 11.8 ± 7.2 | 11.7 ± 7.2 |
Days from first symptoms to randomisation, n | 903 | 918 | 1821 |
Days from first symptoms to randomisation, mean SD | 5.3 ± 3.4 | 5.5 ± 4.2 | 5.4 ± 3.8 |
